Rep. Thomas Kean (R-NJ) Sells Becton, Dickinson and (BDX) Stock
House lawmaker Thomas Kean reported selling shares of medical supply maker Becton, Dickinson and Company.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Thomas Kean (R-NJ) sold between $1,001 and $15,000 of Becton, Dickinson and Company ($BDX) stock on May 21, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 19, 2026.
Since the trade, $BDX is up 1.5% after 1 week, down 3.1% after 1 month and up 32.8% to date (from the $144.37 close on May 21, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Thomas Kean (R-NJ)
- Status:
- Member — House
- State/District:
- NJ-7
- Party:
- republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 19, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Becton, Dickinson and Company ($BDX) | Sell | May 21, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BDX
Becton, Dickinson and Company
Key Points
- Representative Thomas Kean reported the sale of Becton, Dickinson and Company stock valued between $1,001 and $15,000 on May 21, 2026.
- Executive officers at the medical device maker also executed stock sales recently, including Michael Feld and Garrison Michael David.
- Wall Street research firms maintain active coverage on BDX with a consensus buy recommendation and a mean price target of $195.67.
Get $BDX trade alerts by text
We text you when insiders, Congress or big funds trade $BDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Becton, Dickinson and Company alert may contain errors. Disclosures
Lawmaker Discloses Stock Trade in Medical Firm
Representative Thomas Kean, a Republican serving in the House representing New Jersey's seventh district, reported a stock transaction involving Becton, Dickinson and Company, traded on the New York Stock Exchange under the ticker BDX. According to a periodic transaction report filed under the STOCK Act on June 19, 2026, the lawmaker sold shares valued between $1,001 and $15,000. The trade itself took place on May 21, 2026. Disclosures filed by members of Congress provide transparency into personal stock holdings, though they arrive weeks or months after the actual transaction date.
Thomas Kean vs. the S&P 500
Hypothetical returns from Thomas Kean's disclosed trades, not real profit or advice. How we model this.
Recent Insider Transactions at Becton, Dickinson
Corporate insiders at Becton, Dickinson and Company have also adjusted their personal shareholdings through recent open market transactions. On June 24, 2026, executive vice president and division president Garrison Michael David sold 1,100 shares at an average price of $145.66, totaling $160,226 in a planned move. Shortly after on June 26, 2026, chief revenue officer Michael Feld parted with 75 shares at an average price of $152.80 for a total value of $11,460, also under a pre-arranged plan. Insider sales often reflect personal financial planning or diversification needs rather than any shift in company fundamentals.
Wall Street Coverage and Price Targets
Financial institutions keep close tabs on the medical device manufacturer, issuing frequent rating updates and price targets. On October 7, 2026, Barclays began coverage of the stock with an underweight rating and a price target of $165.00. Earlier in August and September, firms including Bank of America Securities, RBC Capital, Citigroup, Piper Sandler, Wells Fargo, and TD Cowen updated their views, with price objectives stretching from $170.00 up to $204.00. Overall, the company carries a consensus buy recommendation backed by 12 analyst opinions.
About Becton, Dickinson and Company
Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company creates medical supplies, devices, laboratory instruments, and diagnostic systems for hospitals, researchers, and clinicians around the globe. Founded in 1897, the company operates across major segments focused on medical essentials, connected care, biopharma systems, and interventional life sciences. Its products range from everyday items like syringes and safety needles to advanced automated specimen testing equipment and vascular access tools.
Looking Ahead to Next Earnings
Investors tracking the healthcare firm will look toward the company's next earnings report, which is scheduled for November 5, 2026, to evaluate quarterly revenue growth and profit margins. Congressional stock disclosures like the one filed by Representative Kean offer a look at lawmakers' personal portfolios, but they do not indicate a broader buying or selling trend for the underlying enterprise.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 3.5%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 86 percent. Operating income missed by 91 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target raises, 1 target cut.
-
Earnings quality
Gross margin up 2.9 points. Operating margin down 8.4 points. Positive free cash flow.
Earnings Call Summary
BDX closed its Waters separation today and reported stronger-than-expected first-quarter results with $5.3 billion in revenue and $2.91 in earnings per share. Growth areas like PureWick and biologic drug delivery are performing well with double-digit gains, though China vaccines and Alaris remain headwinds. Management is investing aggressively in high-growth categories and has already captured 80 GLP-1 molecules in drug delivery devices.
Guidance BDX expects about $12.50 in adjusted earnings per share for the full year, roughly 6 percent growth after tariffs. Management said low single-digit revenue growth is on track. They plan to return $4 billion from the Waters separation through buybacks and debt paydown.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Related Filing Alerts
Source: Thomas Kean's STOCK Act disclosure on $BDX (May 21, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts